title: Smoking-related interstitial lung diseases.
abstract: Cigarette smoke, a toxic collection of thousands of chemicals generated from combustion of tobacco, is recognized as the primary causative agent of certain diffuse interstitial and bronchiolar lung diseases. Most patients afflicted with these disorders are cigarette smokers, and smoking cessation has been shown to be capable of inducing disease remission and should occupy a pivotal role in the management of all smokers with these diffuse lung diseases. The role of pharmacotherapy with corticosteroids or other immunomodulating agents is not well established but may be considered in patients with progressive forms of smoking-related interstitial lung diseases.
authors.affiliation: Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN 55905, USA. ryu.jay@mayo.edu
authors.forename: Robert
authors.initials: R
authors.lastname: Vassallo
authors.forename: Jay H
authors.initials: JH
authors.lastname: Ryu
mesh_terms: D000208:Acute Disease; D001988:Bronchiolitis / Q000175:diagnosis / Q000209:etiology; D002908:Chronic Disease; D003937:Diagnosis, Differential; D006646:Histiocytosis, Langerhans-Cell / Q000175:diagnosis / Q000209:etiology; D006801:Humans; D008168:Lung / Q000000981:diagnostic imaging* / Q000473:pathology* / Q000503:physiopathology; D017563:Lung Diseases, Interstitial / Q000145:classification / Q000175:diagnosis* / Q000000981:diagnostic imaging / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D011649:Pulmonary Alveolar Proteinosis / Q000175:diagnosis / Q000209:etiology; D011657:Pulmonary Eosinophilia / Q000175:diagnosis / Q000209:etiology; D011658:Pulmonary Fibrosis / Q000175:diagnosis / Q000209:etiology; D037721:Pulmonary Surfactant-Associated Protein C / Q000172:deficiency; D012907:Smoking / Q000009:adverse effects*; D014057:Tomography, X-Ray Computed
chemical_list: D037721:Pulmonary Surfactant-Associated Protein C